Vertex Pharmaceuticals (VRTX) recently announced strong financial results with Q2 2025 revenue increasing to $2,965 million from $2,646 million in Q2 2024, and net income turning positive. Despite ...

Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.